Pasithea Therapeutics Corp

Research Pasithea Therapeutics Corp (KTTA) on Bullrun: market cap USD 17.58M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKTTA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 17.58M
• Financial periodFY2025
• Net income-USD 20.43M

Valuation Snapshot

latest market cap is USD 17.58M.

About Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor;

Frequently asked questions

What is Pasithea Therapeutics Corp's market cap?

Pasithea Therapeutics Corp's market capitalization is USD 17.58M.

What does Pasithea Therapeutics Corp do?

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers.